Kiniksa Pharmaceuticals Ltd reports results for the quarter ended in March - Earnings Summary

Kiniksa Pharmaceuticals International

02/05/2023 14:15

* Kiniksa Pharmaceuticals Ltd  KNSA.OQ  reported a quarterly
adjusted loss of 18 cents​​ per share for the quarter ended in
March. The mean expectation of four analysts for the quarter was
for a loss of 21 cents per share.
    * Revenue rose 50.2% to $48.35 million from a year ago;
analysts
expected $46.58 million. 
    * Kiniksa Pharmaceuticals Ltd's reported EPS for the quarter
was a
loss of 18 cents​.
    * The mean earnings estimate of analysts had risen by
about 35.2%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Kiniksa Pharmaceuticals Ltd shares had risen by 2.0% this
quarter and lost 26.7% so far this year.
    * The company reported a quarterly loss of $12.27 million.
    * Wall Street's median 12-month price target for Kiniksa
Pharmaceuticals Ltd is $21.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
2 at 01:15 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.21          -0.18          Beat
 Dec. 31 2022      -0.23          0.06           Beat
 Sep. 30 2022      0.78           3.18           Beat
 Jun. 30 2022      -0.44          -0.29          Beat